Matthias Puls

Revolutionizing Parkinson’s Care – The Future of Closed-Loop Systems

Parkinson’s disease has long challenged medicine with its unpredictability and therapeutic rigidity. Now, digital innovation is enabling a new model—where sensors, AI, and smart delivery systems create therapy that listens, learns, and responds in real time.

Pre-order the book

The future lies in AI-driven dosing algorithms that dynamically adjust drug delivery based on real-time sensor data.

What if your treatment could sense how you're doing—and adjust itself before you even feel the change? Parkinson’s care has long depended on static medication schedules and subjective symptom assessments, leaving patients vulnerable to unpredictable fluctuations. But emerging technologies now make it possible to build intelligent, adaptive therapy systems: powered by wearable sensors, real-time monitoring, and closed-loop drug delivery. Inspired by breakthroughs in diabetes care, these digital health tools are ushering in a new model of responsive, personalized treatment—moving beyond trial-and-error toward precision that evolves with the patient.

When Therapy Thinks Ahead:
A New Era in Parkinson’s Care

What you’ll learn

Why fixed-dose regimens are no longer sufficient in Parkinson’s therapy
How wearable sensors and digital biomarkers enable real-time symptom tracking
What role AI plays in interpreting data and guiding treatment decisions
How automated drug pumps can deliver exactly the right dose at the right time
Which regulatory, technical, and ethical challenges must be overcome

Matthias Puls drives digital transformation in healthcare at the intersection of MedTech and Pharma. He is Managing Director of Puls & Partners Advisory, where he focuses on innovative business models, go-to-market strategies, and business development for digital health solutions – from early concept and clinical validation to market launch and commercialization. Currently, Matthias serves as interim CEO of Ceregate GmbH, advancing the treatment of neurological disorders with its minimally invasive Computer-Brain Interface (CBI) technology. Previously, he directed the global Digital Therapeutics (DTx) and Digital Health Solutions portfolio at Gerresheimer AG, where he was responsible for shaping the company’s digital health strategy and building high-performing teams. Earlier in his
career, Matthias held senior roles at Biotronik and was Managing Director of the Berlin-based digital health start-up Kenkou (cardiovascular biomarkers). He began in international management consulting, most recently at Baringa Partners LLP in Düsseldorf and London, with a focus on strategy, organizational development, and process transformation. In addition, he lectures on digital business models in healthcare at leading European universities.